MedWatch

ALK benefits from Mylan's Epipen woes

Mylan's present difficulties in delivering its adrenalin pen, Epipen, in Britain are benefiting the Danish, allergy-focused pharmaceutical company ALK, which has increased production of its own version of the product in order to meet increasing demand.

ALK has increased production of its adrenalin pen, Jext.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

EU vil beskytte europæiske virksomheder mod USA's Iran-sanktioner

Europæiske virksomheder skal beskyttes mod sanktioner, som USA indfører mod Iran, skriver EU-Kommissionen. I udgangspunktet positivt, men i praksis svært ladsiggørligt vurderer DI, der stadig mener, at danske medicinalselskaber, som opererer i Iran, vil blive ramt negativt. Novo Nordisk afventer situationen.

Her er de vigtigste nyheder fra MedWatch i uge 20

Præsidentielle udfald i USA, fusion i høreapparatsbranchen, rehab-messe i Bella Center og udskiftning i Novo-toppen - MedWatch giver dig overblikket over ugens vigtigste nyheder fra dansk life science. Gik du glip af noget?

Related articles